"increased competition for patients with liver-directed therapies, a new drug approval in salvage metastatic colorectal cancer and restrictions in reimbursement."
How are they going to overcome this increased competition and new drug approval ???
Ann: Trading Update, page-149
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $74.27M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.5¢ | $292.8K | 1.630M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 7394560 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 1260654 | 10 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| SRX (ASX) Chart |